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Background: Safety and efficacy of drug-eluting stents (DES) in saphenous vein graft (SVG) interventions are controversial. We compared 
outcomes of outcomes of DES versus bare-metal stents (BMS) in SVG interventions.
Methods: We performed a multicenter registry assessing clinical outcoms with DES vs. BMS. We included 306 patients who underwent PCI of SVG 
lesions with DES (n=124) or BMS (n=182) with a 2-year follow-up.
Results: The two groups were similar for age, sex, main risk factors, incidence of diabetes (44% for DES and 41% for BMS) use of IIb/IIIa 
antagonists, use of aspiration devices or filters, number of stents and total stent length. Stent diameter was larger for DES vs. BMS (3.9±1.3 vs. 
3.3±0.9 mm, P<0.001).
Overall, incidence of MACE at 2 years was similar in the two groups (35% with BMS vs. 34%, with DES, P=0.55) with an adjusted hazard ratio (HR) of 
0.92 (95% confidence interval 0.6-1.4), with no differences at any time point during the 2-year follow-up (see figure). Also incidence of myocardial 
infarction/death (17% with DES and 15% with BMS, P=0.83) and target vessel revascularization (27% with DES and 32% with BMS, P=0.39) were 
similar in the two groups. Incidence of MACE was also similar in patients with diabetes (50% for BMS and 49% for DES, P=0.67) and in patients with 
grafts <3.5 mm diameter (53% for BMS and 47% for DES, P=0.27).
Conclusions: Our findings do not support use the hypothesis that use of DES may improve outcomes after SVG interventions, even in patients with 
diabetes or with small vessel size. 
